Literature DB >> 15273954

Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.

Margaret May1, Patrick Royston, Matthias Egger, Amy C Justice, Jonathan A C Sterne.   

Abstract

The process of developing and validating a prognostic model for survival time data has been much discussed in the literature. Assessment of the performance of candidate prognostic models on data other than that used to fit the models is essential for choosing a model that will generalize well to independent data. However, there remain difficulties in current methods of measuring the accuracy of predictions of prognostic models for censored survival time data. In this paper, flexible parametric models based on the Weibull, loglogistic and lognormal distributions with spline smoothing of the baseline log cumulative hazard function are used to fit a set of candidate prognostic models across k data sets. The model that generalizes best to new data is chosen using a cross-validation scheme which fits the model on k-1 data sets and tests the predictive accuracy on the omitted data set. The procedure is repeated, omitting each data set in turn. The quality of the predictions is measured using three different methods: two commonly proposed validation methods, Harrell's concordance statistic and the Brier statistic, and a novel method using deviance differences. The results show that the deviance statistic is able to discriminate between quite similar models and can be used to choose a prognostic model that generalizes well to new data. The methods are illustrated by using a model developed to predict progression to a new AIDS event or death in HIV-1 positive patients starting antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273954     DOI: 10.1002/sim.1825

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  29 in total

1.  The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.

Authors:  M Murray; R S Hogg; V D Lima; M T May; D M Moore; S Abgrall; M Bruyand; A D'Arminio Monforte; C Tural; M J Gill; R J Harris; P Reiss; A Justice; O Kirk; M Saag; C J Smith; R Weber; J Rockstroh; P Khaykin; J A C Sterne
Journal:  HIV Med       Date:  2011-08-07       Impact factor: 3.180

2.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.

Authors: 
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

3.  Treatment-Free Survival in Patients With Differentiated Thyroid Cancer.

Authors:  Mousumi Banerjee; David Reyes-Gastelum; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

4.  Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

Authors:  Margaret T May; Suzanne M Ingle; Dominique Costagliola; Amy C Justice; Frank de Wolf; Matthias Cavassini; Antonella D'Arminio Monforte; Jordi Casabona; Robert S Hogg; Amanda Mocroft; Fiona C Lampe; François Dabis; Gerd Fätkenheuer; Timothy R Sterling; Julia del Amo; M John Gill; Heidi M Crane; Michael S Saag; Jodie Guest; Hans-Reinhard Brodt; Jonathan A C Sterne
Journal:  Int J Epidemiol       Date:  2013-04-18       Impact factor: 7.196

5.  Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study.

Authors:  M May; D A Lawlor; P Brindle; R Patel; S Ebrahim
Journal:  Heart       Date:  2006-03-17       Impact factor: 5.994

6.  Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers.

Authors:  Amy C Justice; K A McGinnis; M Skanderson; C C Chang; C L Gibert; M B Goetz; D Rimland; M C Rodriguez-Barradas; K K Oursler; S T Brown; R S Braithwaite; M May; K E Covinsky; M S Roberts; S L Fultz; K J Bryant
Journal:  HIV Med       Date:  2009-09-14       Impact factor: 3.180

7.  Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.

Authors:  Preeyaporn Srasuebkul; Poh Lian Lim; Man Po Lee; Nagalingeswaran Kumarasamy; Jialun Zhou; Thira Sirisanthana; Patrick C K Li; Adeeba Kamarulzaman; Shinichi Oka; Praphan Phanuphak; Saphonn Vonthanak; Tuti P Merati; Yi-Ming A Chen; Somnuek Sungkanuparph; Goa Tau; Fujie Zhang; Christopher K C Lee; Rossana Ditangco; Sanjay Pujari; Jun Y Choi; Jeffery Smith; Matthew G Law
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

8.  Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators.

Authors:  Bryan E Shepherd; Timothy R Sterling; Richard D Moore; Stephen P Raffanti; Todd Hulgan
Journal:  J Clin Epidemiol       Date:  2008-12-23       Impact factor: 6.437

9.  Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.

Authors:  Marcel Zwahlen; Ross Harris; Margaret May; Robert Hogg; Dominique Costagliola; Frank de Wolf; John Gill; Gerd Fätkenheuer; Charlotte Lewden; Mike Saag; Sholmo Staszewski; Antonella d'Arminio Monforte; Jordi Casabona; Fiona Lampe; Amy Justice; Viktor von Wyl; Matthias Egger
Journal:  Int J Epidemiol       Date:  2009-10-09       Impact factor: 7.196

10.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Authors: 
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.